EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Programming cytomegalovirus as an HIV vaccine

Louis J Picker, Jeffrey D Lifson, Michael Gale, Scott G Hansen, Klaus Früh

Trends in Immunology · 2023-04 · 44 (4) · 287-304

DOI: 10.1016/j.it.2023.02.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Immunology, 2023-04. Verfasst von Louis J Picker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA. Electronic ad…. Hauptthemen laut MEDLINE: AIDS Vaccines, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus, Cytomegalovirus Infections. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The initial development of cytomegalovirus (CMV) as a vaccine vector for HIV/simian immunodeficiency virus (SIV) was predicated on its potential to pre-position high-frequency, effector-differentiated, CD8+ T cells in tissues for immediate immune interception of nascent primary infection. This goal was achieved and also led to the unexpected discoveries that non-human primate (NHP) CMVs can be programmed to differentially elicit CD8+ T cell responses that recognize viral peptides via classical MHC-Ia, and/or MHC-II, and/or MHC-E, and that MHC-E-restricted CD8+ T cell responses can uniquely mediate stringent arrest and subsequent clearance of highly pathogenic SIV, an unprecedented type of vaccine-mediated protection. These discoveries delineate CMV vector-elicited MHC-E-restricted CD8+ T cells as a functionally distinct T cell response with the potential for superior efficacy against HIV-1, and possibly other infectious agents or cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusCytomegalovirus InfectionsAnimalsCD8-Positive T-LymphocytesCytomegalovirus

Stichwörter der Autor:innen

HIV vaccineSIV replication arrestcytomegalovirusimmune programming

Substanzen

AIDS Vaccines

Autor:innen und Institutionen

  • Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA. Electronic address: pickerl@ohsu.edu.
  • AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, USA.
  • Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, USA.
  • Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • National Institute of Allergy and Infectious Diseases
  • Bill and Melinda Gates Foundation
  • National Institutes of Health
  • Oregon Health and Science University

Zitieren

APA

Picker, L. J., Lifson, J. D., Gale, M., Hansen, S. G., & Früh, K. (2023). Programming cytomegalovirus as an HIV vaccine. Trends in Immunology, 44(4), 287-304. https://doi.org/10.1016/j.it.2023.02.001

Vancouver

Picker LJ, Lifson JD, Gale M, Hansen SG, Früh K. Programming cytomegalovirus as an HIV vaccine. Trends in Immunology. 2023;44(4):287-304. doi:10.1016/j.it.2023.02.001

BibTeX
@article{Picker2023,
  author = {Picker, Louis J and Lifson, Jeffrey D and Gale, Michael and Hansen, Scott G and Früh, Klaus},
  title = {Programming cytomegalovirus as an HIV vaccine},
  journal = {Trends in Immunology},
  year = {2023},
  volume = {44},
  number = {4},
  pages = {287--304},
  doi = {10.1016/j.it.2023.02.001}
}
Kostenlos starten →